High incidence of late effects found in Hodgkin’s lymphoma survivors, following recall for breast cancer screening

DM Greenfield1, J Wright2, JE Brown1, BW Hancock6,1, HA Davies3, L O’Toole2, C Eiser4, RE Coleman1 and RJ Ross5

1 Academic Unit of Clinical Oncology, Cancer Research Centre, University of Sheffield, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK; 2Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK; 3Sheffield Children’s Hospital Trust, Western Bank, Sheffield S10 2TH, UK; 4Department of Psychology, University of Sheffield, Western Bank, Sheffield S10 2TN, UK; 5Division of Clinical Sciences (North), University of Sheffield, Northern General Hospital, Hemes Road, Sheffield S5 7AU, UK

Assessment of late effects in a cohort of female Hodgkin’s lymphoma patients treated with mantle radiotherapy, identified from the DoH breast cancer screening recall showed high mortality and frequent undiagnosed abnormalities in tissues affected by radiotherapy. With increasing age, this patient group may suffer premature cardiac and respiratory morbidity.

British Journal of Cancer (2006) 94, 469–472. doi:10.1038/sj.bjc.6602974 www.bjcancer.com
Published online 7 February 2006 © 2006 Cancer Research UK

Keywords: breast cancer; Hodgkin’s lymphoma; late effects; mantle radiotherapy

Prolonged disease-free survival is attainable in up to 90% of patients presenting with early-stage Hodgkin’s lymphoma (HL) (Henry-Amar and Joly, 1996). Current treatment usually involves multiagent chemotherapy combined with limited field radiotherapy in selected patients. However, until recently, the standard radiotherapy regimen for supradiaphragmatic HL was the mantle field (Deniz et al, 2003; Horwich and Swerdloff, 2004). Young women who received mantle radiotherapy are at increased risk of breast cancer (Swerdlow et al, 2000; Deniz et al, 2003; Travis et al, 2003; Horwich and Swerdloff, 2004; Kenney et al, 2004). The risk is proportional to radiation dose, and time from treatment (Hancock et al, 1993a; Wolden et al, 1998). Younger age at the time of treatment gives the greatest risk (Hancock et al, 1993a; Bhatia et al, 1996). At 25 years of follow-up, the cumulative risk of breast cancer for women treated between 10 and 19 years of age is reported as 15 – 33%, and for those treated between the ages 20 and 29 years, 15 – 25% (Horwich and Swerdloff, 2004). In 2003, the UK Department of Health launched a ‘Patient Notification Exercise’ to inform patients of the increased breast cancer risk. The exercise mandated recall of all women with HL, who were diagnosed at or below the age of 35 from 1962 onwards. Mantle radiotherapy is associated with other long-term complications including second malignancies, and disorders of the thyroid, heart and lung (Morgan et al, 1985; Gustavsson et al, 1990; Allavena et al, 1992; Gustavsson et al, 1992; Henry-Amar and Joly, 1996). The aim of our study was to investigate the incidence of late effects in women recalled in the UK ‘Patient Notification Exercise’.

MATERIALS AND METHODS

Patients were identified from a network database, according to the following criteria: diagnosis of HL after 1962 and before the age of 35 years, and mantle radiotherapy. Women with a known history of breast cancer were excluded. Patients were offered a clinic appointment for counselling regarding breast cancer risk. Patients who accepted were asked if they were willing to participate in a study of late effects. The study was approved by the South Sheffield Research Ethics Committee and all patients gave written informed consent.

Late effects study protocol

Patients underwent a clinical evaluation including examination of the skin and thyroid. In addition, the following investigations were performed:

Blood: Serum thyroid-stimulating hormone (TSH), free T4 (fT4), parathyroid hormone and corrected calcium.
Cardiac: Echocardiogram and electrocardiogram.
Respiratory: Spirometry and diffusion capacity (TLCO).

Measurement and interpretation of results

Serum measurements were considered against the laboratory normal range. Spirometry and transfer factors results were expressed as the percentage of predicted. All cardiology and respiratory tests were reviewed by a single cardiologist and respiratory physiologist, respectively. Tests were reviewed without the knowledge of patients’ characteristics or other study data.

Cardiac and respiratory abnormalities were classified as follows:

Major cardiac abnormality:
- A reduction in ejection fraction to less than 50% (or LV fractional shortening of less than 28%).

Correspondence: Professor BW Hancock;
E-mail: b.w.hancock@sheffield.ac.uk
Received 15 November 2005; revised 4 January 2006; accepted 5 January 2006; published online 7 February 2006
• Regurgitant valvular lesion of more than mild severity.
• Valvular stenosis.
• Raised pulmonary artery pressure (> 40 mmHg) or right heart dilatation.

Minor cardiac abnormalities:

• Other reported anomalies including the presence of valve leaflet thickening and regional left ventricular wall motion abnormality.

Major respiratory abnormality:

• Restrictive defects: Total lung capacity reduced (normal range is 80–120% predicted) with preservation of FEV₁/FVC ratio >80%, but evidence of reduced TLCO.
• Obstructive defect: FEV₁/FVC <70%.

Minor respiratory abnormality:

• Isolated reduction in TLCO (<80%).

Statistical analysis

Descriptive statistics were calculated using SPSS v11.

RESULTS

Cohort characteristics

A total of 131 women previously treated with mantle radiotherapy for HL was identified, and of these, 11 were deceased, eight had a history of breast cancer and 11 were lost to follow-up. The remaining 101 were invited to attend a specialist clinic for advice about breast cancer as part of the UK ‘Patient Notification Exercise’, and 24 declined or did not respond. A total of 77 patients attended, and of these, 58 women agreed to participate in the late effects study (Table 1).

Mortality

Of the initial cohort of 131 patients, 12 (9.2%) died including one woman with oesophageal squamous carcinoma diagnosed during the study. Five patients died from cardiac causes, four from secondary cancers, two from respiratory causes and one from infection.

Second neoplasms

Of the 131 patients, 13 (9.9%) were identified to have had a second cancer. Eight had a history of breast cancer, two of whom died from metastatic disease, two patients had a history of basal cell carcinomas in the radiation field and one patient each had an oesophageal squamous carcinoma, cardiac sarcoma and lung cancer, respectively.

Table 1  Characteristics of women previously treated with mantle radiotherapy for HL who participated in late effects study

| Characteristic                  | Detailed late effects study |
|--------------------------------|-----------------------------|
|                                | N   | Mean (range) | s.d. |
| Age at diagnosis (years)       | 58  | 23.3 (7–34)  | 5.8  |
| Time since diagnosis (years)   | 58  | 17 (4–36)    | 8.8  |
| Height (cm)                    | 58  | 164.6 (151–180) | 6.4  |
| Weight (kg)                    | 56  | 73.3 (47.7–134.0) | 16.7 |

HL = Hodgkin’s lymphoma; s.d. = standard deviation.

Breast screening

Thus far, no incident breast cancers have been identified at the first breast screen.

Late effects study

Most of the 58 patients included in the late effects study received a radiation dose of 35 Gy in 19 fractions. Of whom, 42 (72%) also received chemotherapy (10 different regimens, the most frequent being LOPP (LOPP = Chlorambucil, Vincristine, Procarbazine, Prednisolone) and MOPP (MOPP = Nitrogen Mustard, Vincristine, Procarbazine, Prednisolone)). Also, 24 women received doxorubicin and 19 women received bleomycin. as a result of relapse, seven women also received second-line chemotherapy.

Skin  No new cancers were detected during clinical examination, although one person was referred to dermatology with a suspicious lesion that was shown to be benign.

Thyroid and parathyroid  In all, 21 patients (36.2%) were already receiving thyroid replacement. Six (10.2%) were found to have a previously undiagnosed goitre or thyroid nodule and four (6.8%) untreated women were found to have a raised TSH level, suggesting undiagnosed hypothyroidism. Of those patients with goitres, all have undergone surgery with no evidence of malignancy on histology. Parathyroid hormone and calcium levels were normal in all patients.

Cardiovascular  In all, 10 patients (17.2%) had a major cardiac abnormality: five had evidence of mixed aortic abnormality; three had mitral regurgitation, one had a mitral/aortic valve replacement; and five had a reduction in ejection fraction of less than 50% (Table 2).

Respiratory function  Twenty patients had a major respiratory abnormality: fourteen women (24%) had evidence of airway obstruction and six women (10.3%) had restrictive lung defect (Table 2).

Incidence of medical problems  Overall, 42 (72%) of the 58 women who underwent detailed evaluation had a previously undiagnosed medical problem (Table 2).

DISCUSSION

In a cohort of HL women, mean age 40 years, previously treated with mantle radiotherapy, 9.2% had died a nonlymphoma-related death and we found a high incidence of undiagnosed medical problems in survivors. Impressively, no patient had died of HL. At a mean of 17 years post-treatment, 72% of women had a medical problem that could relate to their previous treatment. In addition to radiotherapy, chemotherapy had also been received by 72% of patients and it should be recognised that this may contribute to some late effects (Henry-Amar, 2000). In addition, it is possible that there is a genetic risk for both HL and late effects, although to date there is no evidence to support an underlying association between the two.

We found a 9.9% cumulative incidence of secondary malignancy. This incidence is similar to the 10.6% reported at 20 years post-treatment in adult survivors of childhood HL (Bhatia et al, 2003), although lower than 21.9% at 25 years in a population of 32 591 survivors of HL (Dores et al, 2002). The most common cancer was breast cancer, as reported previously (Kenney et al, 2004). Increasing age over 50 years is associated with a greater cancer burden (Dores et al, 2002) and one of our patients aged 57 years was diagnosed and died from oesophageal cancer during the course of our study. None of this cohort developed leukaemia. The
risk of leukaemia in patients treated for HL has been estimated at 0.3% after radiotherapy alone, 2.8% after chemotherapy alone and 5.4% in combined modality therapy (Brusamolino et al., 1998). A more recent study (Okines et al., 2005) estimated the incidence of second primary malignancies in patients treated for HL, including the risk of haematological malignancy. This risk was low at only 0.55% and this is consistent with our findings.

Radiation-induced damage to the heart has been recognised for some time (Gustavsson et al., 1990; Hancock et al., 1993b; Adams et al., 2004). The spectrum of damage ranges from constrictive pericarditis, significant valvular defects, to reduced systolic dysfunction. In the largest study (Hancock et al., 1993b), of 2232 Hodgkin’s patients, 3.9% died from heart disease and the relative risk for heart disease was 3.1. The risk was greater with increased mediastinal radiation and the risk of myocardial infarction increased with duration of time after treatment. Our results confirm the high incidence of cardiac abnormalities in this patient group.

In the lungs, mediastinal radiation appears to create predominantly a restrictive rather than obstructive defect (Allavena et al., 1992; Gustavsson et al., 1992; Nysom et al., 1998). Hodgkin’s patients (64–84%) treated with mantle radiotherapy had a reduction in lung perfusion and perfusion appeared to be more affected than ventilation, suggesting a primary vascular lesion (Allavena et al., 1992; Gustavsson et al., 1992). However, in patients treated during childhood, there was a reduction in lung volumes as well as transfer factor (Nysom et al., 1998). Our results are consistent with these observations, although we found a higher incidence of obstructive defects. This is likely to relate to confounding environmental factors, including smoking and occupation.

Hypothyroidism, thyroid nodules and thyroid cancer are well-recognised complications of mantle radiotherapy (Morgan et al., 1985; Sklar et al., 2000). Consistent with this, we found that 36.2% of Hodgkin’s patients were already receiving thyroxine treatment. However, of concern, we found clinically apparent undetected

### Table 2

| Age at study (years) | Number of years of follow-up | Mantle radiation dose (Gy) (fractionation) | Cumulative dose of doxorubicin (mg m⁻²) | Thyroid abnormality | Echo abnormality | Lung defects |
|----------------------|-----------------------------|------------------------------------------|----------------------------------------|-------------------|-----------------|------------|
| 50.1                 | 25                          | 35 (19)                                  | 393.0                                  | Goitre            | Major           | Restrictive |
| 30.7                 | 12                          | 38.5 (22)                                | 240.0                                  | Goitre Minor      | Obstructive     | Reduced TLCO|
| 34.7                 | 17                          | 35 (19)                                  | 330.0                                  | Goitre Minor      | Obstructive     | Reduced TLCO|
| 39.1                 | 12                          | 35 (20)                                  | 383.0                                  | Goitre Minor      | Obstructive     | Reduced TLCO|
| 47.4                 | 9                           | 35 (20)                                  | 204.0                                  | Goitre             | Obstructive     | Reduced TLCO|
| 40.9                 | 6                           | 35 (20)                                  | 360.0                                  | Raised TSH Minor  | Obstructive     | Reduced TLCO|
| 37.0                 | 5                           | 35 (20)                                  | 240.0                                  | Goitre            | Major           | Restrictive |
| 46.7                 | 17                          | 35 (19)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 46.9                 | 26                          | 30 (19)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 52.6                 | 35                          | 35 (20)                                  | 236.0                                  | Thyroid           | Major           | Restrictive |
| 41.4                 | 7                           | 35 (20)                                  | 284.0                                  | Thyroid           | Major           | Restrictive |
| 41.9                 | 9                           | 35 (20)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 43.2                 | 11                          | 35 (20)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 36.3                 | 9                           | 35 (20)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 54.2                 | 33                          | 35 (20)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 47.3                 | 25                          | 35 (20)                                  | 195.0                                  | Thyroid           | Major           | Restrictive |
| 53.4                 | 29                          | 37.5 (24)                                | 360.0                                  | Thyroid           | Major           | Reduced TLCO|
| 37.8                 | 23                          | 35 (19)                                  | 195.0                                  | Thyroid           | Major           | Reduced TLCO|
| 38.6                 | 21                          | 35 (20)                                  | 236.0                                  | Thyroid Major     | Obstructive     | Reduced TLCO|
| 36.1                 | 16                          | 35 (20)                                  | 284.0                                  | Thyroid Major     | Obstructive     | Reduced TLCO|
| 41.6                 | 16                          | 35 (20)                                  | 284.0                                  | Thyroid Major     | Obstructive     | Reduced TLCO|
| 27.1                 | 10                          | 35 (20)                                  | 225.0                                  | Thyroid Major     | Obstructive     | Reduced TLCO|
| 56.9                 | 36                          | 27.4 (20)                                | 480.0                                  | Raised TSH        | Major           | Reduced TLCO|
| 53.6                 | 27                          | 35 (19)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 40.6                 | 27                          | 35 (18)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 41.6                 | 24                          | 35 (19)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 39.2                 | 8                           | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 47.4                 | 23                          | 35 (19)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 36.6                 | 10                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 33.4                 | 16                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 34.5                 | 10                          | 36.75 (21)                               | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 41.6                 | 10                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 50.0                 | 31                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 47.8                 | 29                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 42.5                 | 24                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 36.5                 | 17                          | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 43.6                 | 28                          | 35 (19)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 35.3                 | 9                           | 35 (20)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|
| 47.7                 | 19                          | 35 (19)                                  | 480.0                                  | Goitre Major      | Obstructive     | Reduced TLCO|

TSH = thyrotropin; TLCO = transfer factor. Major cardiac abnormalities include: aortic valve disease, mitral regurgitation, mitral and aortic valve replacement and left ventricular impairment (EF < 50%). Minor cardiac abnormalities include: valve leaflet thickening, regional abnormality of LV wall, mild aortic or mitral valvular regurgitation.
thyroid nodules in 10.2% of patients and raised TSH levels in 6.8% of patients. In the data from the Childhood Cancer Survivor Study, hypothyroidism was the most common disturbance with a relative risk of 17.1; the relative risk of thyroid nodules compared to a sibling was 27 and thyroid cancer 18 (Sklar et al, 2000). We found no abnormality of calcium homeostasis, suggesting that the parathyroid glands are relatively resistant to radiation-induced damage, consistent with previous reports (Milenyi et al, 2004). We have screened patients treated with mantle radiotherapy as part of a national recall for breast cancer screening. In the process, we have identified that this patient group had a high incidence of undiagnosed late effects of cancer therapy. The mean age of our patients was 40 years and it is likely that with age, they will have an increasing burden of late effects and therefore the need for follow-up increases with time from the end of treatment.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Weston Park Hospital Cancer Appeal. We are grateful to Lesley Turner for trial coordination and data management and to Kathy Billings for respiratory physiology expertise.

REFERENCES

Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22: 3139 – 3148

Allavena C, Conroy T, Alletti P, Bey P, Lederlin P (1992) Late cardiopulmonary toxicity after treatment for Hodgkin’s disease. Br J Cancer 65: 908 – 912

Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996: 745 – 751

Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan B, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 21: 4386 – 4394

Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lurghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C (1998) The risk of acute leukemia in patients treated for Hodgkin’s disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 83: 812 – 823

Deniz K, O’Mahony S, Ross G, Purushotham A (2003) Breast cancer in women after treatment for Hodgkin’s disease. Lancet Oncol 4: 207 – 214

Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Juenasui T, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484 – 3494

Gustavsson A, Eskilsson J, Landberg T, Larusdottir H, Svanh-Tapper G, White T, Wollmer P (1992) Long-term effects on pulmonary function of mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol 3: 455 – 461

Gustavsson A, Eskilsson J, Landberg T, Svanh-Tapper G, White T, Wollmer P, Akerman M (1990) Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol 1: 355 – 363

Hancock SL, Tucker MA, Hoppe RT (1993a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85: 25 – 31

Hancock SL, Tucker MA, Hoppe RT (1993b) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. J Am Med Assoc 270: 1949 – 1955

Henry-Amar M (2000) Long-term problems. In Malignant Lymphoma, Hancock BW, Selby PJ, MacLennan K, Armitage JO (eds), Vol. 1, pp 421 – 436. London: Arnold

Henry-Amar M, Joly P (1996) Late complications after Hodgkin’s disease. Ann Oncol 7(Suppl 4): 115 – 126

Horwich A, Swerdlow AJ (2004) Second primary breast cancer after Hodgkin’s disease. Br J Cancer 90: 294 – 298

Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L (2004) Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Int Med 141: 590 – 597

Milenyi Z, Keresztes K, Lakos G, Varoczy L, Milenyi L, Illes A (2004) Is the treatment of Hodgkin’s disease detrimental to the parathyroid gland? Acta Haematol 112: 148 – 151

Morgan GW, Freeman AP, McLean RG, Jarvie BH, Giles RW (1985) Late cardiac, thyroid and pulmonary sequelae of mantle radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11: 1925 – 1931

Nysom K, Holm K, Hertz H, Hesse B (1998) Risk factors for reduced pulmonary function after malignant lymphoma in childhood. Med Pediatr Oncol 30: 240 – 248

Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW (2005) Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 93: 418 – 424

Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L (2000) Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85: 3227 – 3232

Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18: 498 – 509

Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van’t Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice Jr JD, Gilbert E (2003) Breast cancer following radiotherapy and chemotheray among young women with Hodgkin’s disease. J Am Med Assoc 290: 465 – 475

Wolden SL, Lamborn KR, Cleary SF, Tate JT, Donaldson SS (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16: 536 – 544